The medication Letrol (Letrozole) provides targeted therapeutic support for individuals with hormone receptor-positive malignancies, focusing on the management of the hormone-driven disease activity and addressing the risk of recurrence.

This treatment is commonly used across conditions presenting with systemic discomfort, specifically in clinical scenarios related to early breast cancer, locally advanced disease, metastatic disease, and as extended adjuvant therapy after initial treatment. This usage is relevant when supportive symptom management is appropriate.

Controlling Hormone-Driven Malignancy Growth

This therapeutic domain addresses conditions characterized by periods of heightened symptoms where disease activity is dependent on circulating estrogen. The medication helps provide long-term therapeutic assistance to manage this systemic imbalance, which contributes to improved comfort during periods of heightened symptoms by is applied in managing the manifestation of hormone-driven disease activity. This is commonly used in advanced or metastatic presentations.

Reducing the Risk of Disease Recurrence

Letrol is commonly applied as a critical component of the adjuvant and extended adjuvant therapeutic plans following initial local therapy. This treatment is used for managing the risk of the disease returning, which supports patients during episodes of heightened discomfort by provides supportive relief that helps address the potential for future disease activity. This usage assists with maintaining functional stability by is used in addressing the risk of the disease returning.

Regulatory References

1. official FDA labeling hosted by NIH DailyMed

The medicine Letrol is authorized for use primarily in postmenopausal women. Eligibility is strictly defined by an individual's hormonal status, reproductive potential, and specific underlying health conditions, as documented in official government regulatory labels.

Eligibility Scope

Eligibility Classifications (High-Level)

Resulting Eligibility Structure

Official Eligibility Statements:

• Letrol is indicated for use in postmenopausal women.
• The medicine is contraindicated in women with a premenopausal endocrine status.
• Use is contraindicated during pregnancy and breastfeeding.
• A reduced dose schedule is required for patients with severe hepatic impairment.
• The medicine is not recommended for use in children and adolescents.

Connection to the overall eligibility profile Regulatory documents establish that only women with a confirmed postmenopausal endocrine status are eligible to use Letrol. Use is prohibited for premenopausal women, pregnant women, and those with a known hypersensitivity to the drug. For patients with severely impaired liver function, the official labeling requires a dose modification, and use in the pediatric population is officially not recommended.

Interactions with other medicines and products

The official interaction profile for Letrol (Letrozole) establishes specific constraints regarding co-administration, primarily due to pharmacodynamic conflict and metabolic pathway involvement.

Documented Pharmacokinetic and Pharmacodynamic Conflicts

Co-administration with estrogen-containing products, including Hormone Replacement Therapy (HRT) or certain supplements, is officially contraindicated due to pharmacodynamic antagonism that prevents Letrol from achieving its therapeutic goal of estrogen suppression. Similarly, the regulatory label advises against combining Letrol with Tamoxifen, as documented pharmacokinetic studies show that Tamoxifen can significantly reduce the plasma concentration of Letrol itself.

Letrol is officially documented as an inhibitor of CYP2A6 (strong) and CYP2C19 (moderate). Caution is indicated when co-administering Letrol with medicines whose clearance is heavily dependent on these isoenzymes and that possess a narrow therapeutic index.

Population and Administration Context

Patients with severe hepatic impairment (Child-Pugh C) experience a significant increase in systemic exposure to Letrol due to impaired drug clearance, which is a key interaction-relevant population factor. Letrol's administration is not significantly affected by food, meaning it can be taken independently of meal timing. However, combining Letrol with alcohol may increase the documented risk of central nervous system effects such as dizziness and somnolence.

Selective Aromatase Enzyme Inhibition

The core mechanism of Letrol (Letrozole) is the selective, reversible inhibition of the Aromatase enzyme (Cytochrome P450 19A1, CYP19A1). The drug functions as a non-steroidal Type II inhibitor by engaging in competitive binding to the enzyme's heme group. This action provides a focused effect on this molecular entity, directly interfering with its catalytic function.

Endocrine Biosynthesis Blockade

This action results in the significant inhibition of the final step in the steroidogenesis pathway, known as aromatization. Letrozole prevents the conversion of androgens (e.g., androstenedione) into estrogens (e.g., estrone and estradiol) in peripheral tissues. This cascade leads to a profound, systemic depletion of circulating estrogen, facilitating a subsequent physiological adjustment. The selective action provides focused inhibition with limited interaction with other adrenal enzyme systems, maintaining the synthesis of hormones such as cortisol.

️ Physiological Constraint

The mechanism is primarily effective against peripheral Aromatase activity, rendering it less relevant when estrogen is predominantly produced by high-output premenopausal ovaries. The function is also constrained by the potential for acquired resistance due to the upregulation of non-hormonal growth factor pathways, which may supersede the need for estrogenic stimulation.

Official Administration Principles

Letrol, containing the active ingredient Letrozole, is administered exclusively through the oral route as a 2.5 mg film-coated tablet. The medicine is taken as a single tablet once daily (qDay) on a continuous basis for all approved adult indications. This standardized dosing pattern is intended to establish consistent systemic exposure of the compound.

The medicine may be ingested with or without food and should be taken at approximately the same time each day to maintain the regularity of the dosing schedule. If a dose is missed, it is recommended to take it as soon as the patient remembers; however, if the time is near the next scheduled dose, the missed dose should be skipped entirely to prevent taking more than the 2.5 mg daily dose.

Duration and Specific Adjustments

The duration of treatment is determined by the specific clinical context. For standard adjuvant therapy, the typical usage period is five years. Conversely, in the context of advanced or metastatic disease, administration continues until progression of the condition is documented.

For most older adults and patients with mild to moderate kidney or liver impairment, no dosage adjustment is required. A specific modification is necessary only for individuals with severe hepatic impairment (Child-Pugh C), where the dosage is reduced to 2.5 mg administered every other day. This modification reflects the necessary adjustment for reduced metabolism in this specific population.

Research Evidence / Overview of Studies for Letrol

Evidence for Use in Locally Advanced or Metastatic Disease

The research supporting the use of Letrol for locally advanced or metastatic hormone receptor-positive disease primarily comes from large-scale, controlled clinical trials. These studies, which involved postmenopausal women, were conducted during periods of increased symptom activity and compared Letrol against older types of endocrine therapy or placebo. The research examined outcomes that describe the disease course, such as monitoring the time until progression (Progression-Free Survival or PFS), the percentage of patients where an Objective Response Rate (a measure of tumor size reduction) was observed, and Overall Survival (OS).

Initial findings from these trials reported measurements of tumor status and the observed time during which disease progression was not documented. What remains uncertain is the interpretation of final, long-term Overall Survival data. In some older trials, patients in the comparison group were allowed to switch to Letrol when their disease progressed, which can complicate the analysis of long-term survival for the entire group.

Evidence for Use in Adjuvant Therapy

Research for the adjuvant use of Letrol—meaning treatment given after primary local therapy to address the potential for future disease activity—is drawn from major international Phase III Randomized Controlled Trials (RCTs). These studies explored the outcomes where Letrol was used for a standard duration (typically five years) compared with older anti-estrogen therapies. The central outcome monitored was Disease-Free Survival (DFS), which is defined as the time until the disease recurs or a new primary cancer develops, and Overall Survival (OS).

Studies monitored outcomes where Letrol was evaluated against other endocrine therapies, and the findings described patterns related to DFS and OS. A research limitation is that while studies monitor long-term survival, specific comparative evidence between individual drugs within the class remains limited.

Research Gaps and What is Still Uncertain About Letrol

While a large amount of clinical research exists, certain areas remain under active study or have limited data. For instance, the long-term effects of Letrol on specific markers like bone density or cardiovascular outcomes, when compared directly to other drugs in the same class, are not entirely conclusive across all trials. Furthermore, data for certain unique subgroups, such as older adults with multiple pre-existing conditions, or populations outside of the primary trial criteria, are still emerging.

Key Studies & References Letrozole (Letrol) Official FDA Labeling and Patient Information

Common questions about Letrol (FAQ)

Q: What is the purpose of Letrol in treating breast cancer?

Official regulatory documents indicate that Letrol is authorized for use in the treatment of certain types of breast cancer in women who are postmenopausal. It is approved for managing both early breast cancer (known as adjuvant treatment) and for advanced or metastatic disease.

Q: I have liver problems; do I need to change my dose of Letrol?

Official prescribing information indicates that for patients with mild to moderate liver impairment, a dosage change may not be required. However, for severe liver impairment (Child-Pugh C), the official label recommends a specific dose adjustment because of altered drug processing in this population.

Q: Does Letrol interact with any other common medications?

Official information advises against combining Letrol with other anti-estrogen medicines, such as Tamoxifen, or products that contain estrogen, like certain hormone replacement therapies. Caution is also indicated with other medicines that have a narrow therapeutic range and whose breakdown depends heavily on the CYP2A6 and CYP2C19 liver enzymes.

Q: How is Letrol administered? Is it an injection?

Letrol is only available and administered as an oral, film-coated tablet that is taken by mouth. Official prescribing information confirms that it is not available in an injectable form.

Q: When does the medicine begin to have its intended hormonal effect?

Studies on how the medicine works in the body show that the significant reduction in circulating estrogen levels begins within two to three days after the first dose. The drug's concentration in the body is generally expected to reach a steady state, or stable level, within two to six weeks of daily use.

Q: Is Letrol a type of chemotherapy?

No. Official regulatory documents classify Letrol as a nonsteroidal aromatase inhibitor, which is a specific type of endocrine therapy, also known as hormonal therapy. It is not considered a traditional chemotherapy drug.

How to Store and Dispose of Letrol?

The storage and disposal instructions for Letrol (Letrozole) are officially defined to maintain drug stability and ensure safety.

For disposal, unused or expired Letrol must not be flushed down a toilet or drain, as this can negatively impact the environment. Official guidelines recommend using a drug take-back program or mixing the medication with an unappealing substance, such as dirt or coffee grounds, sealing it in a plastic bag, and discarding it in the household trash. Caregivers should also wash their hands after handling the tablets.